Stephen V Liu: Is there value in continuing osimertinib beyond progression?
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a recent article by Tejas Patila on X:
“Is there value in continuing osimertinib beyond progression?
Retrospective analysis in Lung Cancer Journal showed longer PFS with continuing TKI – but this is still an open question that will be answered with the prospective COMPEL trial.”
Authors: Tejas Patila, Dexiang Gaob, Alexander Watsona, Mandy Sakamotoa, Yunan Niec, Amanda Gibsond, Michelle L Deand, Benjamin A. Yodera, Eliza Millera, Margaret Stalkere, Dara L. Aisnerf, Paul A. Bunna, Erin L. Schenka, Melina E. Marmarelise, Chiara Bennatig, Vishal Navanid, Yongchang Zhangh and DRoss Camidge
In this study, 50 patients continued osi with chemotherapy post progression and 109 had chemotherapy alone. PFS was longer with continuing osi (9 vs 4.5m) and there was a longer time to CNS progression in pts without brain metastases.
Subject to some selection bias, access amplifies socioeconomic disparities, and retrospective analysis shows association but not causation. I do think it is reasonable and have done it routinely – though now, MARIPOSA2 with amivantamab + chemotherapy (below) is my standard.
Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.
More posts featuring Stephen V Liu.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023